Press Release
15 Mar, 2021
48
InnoCare to Hold 2021 R&D Day on April 15, 2021
3332
11 Mar, 2021
45
InnoCare to Host 2020 Full Year Earnings Call on March 29, 2021
3327
05 Feb, 2021
115
Beijing, Feb. 5, 2021 —— InnoCare Pharma (HKEX: 09969), a leading biopharmaceutical company, announced today that China National Medical Products Administration (NMPA) has approved the clinical trial of Bruton’s tyrosine kinase (BTK) inhibitor orelabrutinib in combination with R-CHOP for previously untreated patients with mantle cell lymphoma (MCL).
3306